ScholarIQanswers from OpenAlex & ORCID
Cora N. Sternberg
ResearcherPublications, citations & collaboration network
Cora N. Sternberg is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Cora N. Sternberg have?
ScholarIQindexed works
Cora N. Sternberg has 954 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Cora N. Sternberg have?
ScholarIQcitation count
Cora N. Sternberg has 73,939 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Cora N. Sternberg?
ScholarIQh-index
Cora N. Sternberg has an h-index of 110 in OpenAlex.
What is the i10-index of Cora N. Sternberg?
ScholarIQi10-index
Cora N. Sternberg has an i10-index of 436 in OpenAlex.
What is the ORCID of Cora N. Sternberg?
ScholarIQorcid
The ORCID for Cora N. Sternberg is on the source record.
What is the OpenAlex record for Cora N. Sternberg?
ScholarIQopenalex
The OpenAlex for Cora N. Sternberg is on the source record.
What are the most-cited papers on Cora N. Sternberg?
ScholarIQmost cited works
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher, Karim Fizazi, Fred Saad, Mary‐Ellen Taplin, Cora N. Sternberg, Kurt Miller, Ronald de Wit, Peter F.A. Mulders, Kim N., Neal D. Shore, Andrew J. Armstrong, Thomas W. Flaig, Aude Fléchon, Paul N. Mainwaring, Mark T. Fleming, John D. Hainsworth, Mohammad Hirmand, Bryan Selby, Lynn Seely, Johann S. de Bono
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono, Christopher J. Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N., Robert J. Jones, Oscar B. Goodman, Fred Saad, John Staffurth, Paul N. Mainwaring, Stephen Harland, Thomas W. Flaig, Thomas E. Hutson, Tina Cheng, Helen Patterson, John D. Hainsworth, Charles J. Ryan, Cora N. Sternberg, Susan Ellard, Aude Fléchon, Mansoor N. Saleh, Mark C. Scholz, Eleni Efstathiou, Andrea Zivi, Diletta Bianchini, Yohann Loriot, Nicole Chieffo, Thian Kheoh, Christopher M. Haqq, Howard I. Scher
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf, Yohann Loriot, Cora N. Sternberg, Celestia S. Higano, Peter Iversen, Suman Bhattacharya, Joan Carles, Simon Chowdhury, Ian D. Davis, Johann S. de Bono, Christopher P. Evans, Karim Fizazi, Anthony M. Joshua, Choung‐Soo Kim, Go Kimura, Paul N. Mainwaring, Harry H. Mansbach, Kurt Miller, Sarah B. Noonberg, Frank Perabo, De Phung, Fred Saad, Howard I. Scher, Mary‐Ellen Taplin, Peter Venner, Bertrand Tombal
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
Howard I. Scher, Susan Halabi, Ian F. Tannock, Michael J. Morris, Cora N. Sternberg, Michael A. Carducci, Mario A. Eisenberger, Celestia S. Higano, Glenn J. Bubley, Robert Dreicer, Daniel Petrylak, Philip W. Kantoff, Ethan Basch, William Kevin Kelly, William D. Figg, Eric J. Small, Tomasz M. Beer, George Wilding, Alison Martin, Maha Hussain